1249044-16-3

Usage

Appearance

White to off-white crystalline powder

Melting point

Around 90-92°C

Usage

Building block in the synthesis of pharmaceuticals and agrochemicals

Specific application

Production of sulfonyl cyanamides

Field of application

Medicinal chemistry

Additional use

Development of innovative chemical processes

Role

Key intermediate in the preparation of various chemical compounds

Safety and environmental considerations

Proper storage, handling, and disposal procedures should be followed

Upstream product

• 107-06-2 1,2-dichloro-ethane 
• 2274-42-2 methanesulfonyl-acetonitrile 
• 106-93-4 ethylene dibromide 

Downstream Products

• 1628734-96-2 (1-(methylsulfonyl)cyclopropyl)methanamine hydrochloride 
• 1600513-01-6 N-(2-(5-bromo-2-fluorophenyl)-1-((1-cyanocyclopropyl)sulfonyl)-3-fluoropropan-2-yl)-2-methylpropane-2-sulfinamide 
• 1600512-97-7 N-((R)-2-(5-bromo-2-fluorophenyl)-1-((1-cyanocyclopropyl)sulfonyl)propan-2-yl)-2-methylpropane-2-sulfinamide 
• 1403469-25-9 C₁₃H₁₄FN₃O₄S 

Relevant academic research and scientific papers

2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use

In its many embodiments, the present invention provides certain iminothiazine dioxide compounds, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of the variables shown in the formula are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.

AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.

2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE

In its many embodiments, the present invention provides provides certain iminothiazine dioxide compounds, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of the variables shown in the formula are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed

DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES

The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.